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Background: The AXXESS system is a Biolimus A9-eluting self expanding stent, dedicated to the treatment of bifurcation coronary lesions. The 
objective of the DIVERGE study was to evaluate the safety and effectiveness of this stent.
Methods: 302 patients were enrolled from June 2006 to October 2007, with 299 patients receiving the AXXESS stent. Distal branch vessel disease 
was treated with Cypher (1.67 branch stents per patients). Patients were followed up at 1, 9, 12, and 24 months for any major adverse cardiac 
events, its components, and stent thrombosis. Data were collected via electronic forms and analyzed at a centralized data coordinating center. 
Source document verification was conducted by independent monitors for all patients. Major adverse cardiac events (death, Q- or Non-Q-wave 
myocardial infarction, or target lesion revascularization) were adjudicated according to study definitions. Any stent thrombosis was adjudicated 
according to ARC definitions.
Results: At 1 year follow up, the overall MACE rate was 9.3%. Q-wave MI was 1.0%, and non-Q-wave MI was 3.3%. Ischemia driven TLR was 6.0% 
(5% PCI and 1% CABG). Despite frequent use of multiple stents, late stent thrombosis was 0.3%. 
Conclusion: At 1 year follow up, the AXXESS stent maintains MACE below 10% in de novo bifurcation lesions. Two year follow up is ongoing and will 
be available for the presentation.
